21:36 (GMT +7) - Friday 23/04/2021


AstraZeneca Vietnam obtains import & export license

Released at: 14:03, 25/12/2019

AstraZeneca Vietnam obtains import & export license

Photo: AstraZeneca

License enables biopharmaceutical firm to further improve Vietnamese people's health and well-being.

by Khanh Chi

Sweden pharmaceutical giant AstraZeneca Vietnam last week announced it has received a Certificate of Satisfaction of Conditions for the Pharmacy Business. By meeting all conditions regulated in Decree No. 54 dated May 2017 issued by the government, AstraZeneca is now able to import and export innovative treatment products to and from Vietnam, hence delivering greater values to local patients.

“We are grateful for the support and guidance from the government, involving ministerial offices and our partners in Vietnam, to allow AstraZeneca to establish greater collaboration with the local pharmaceutical industry,” said Mr. Nitin Kapoor, Chairman of AstraZeneca Vietnam.

“The license allows us to take a significant step towards transforming our business model to provide patients faster access to innovative medicines and contribute to the development of the healthcare sector in Vietnam.”

AstraZeneca Vietnam has also received principal approval for conducting R&D activities in Vietnam. The company aims to conduct more research programs, addressing the needs of Vietnamese patients as well as providing an uplift in biomedical expertise in the country.

In the past five years, AstraZeneca, through its representative office, has been supporting its Global R&D team to become the leading initiator of clinical research in Vietnam, with a robust network of more than 130 research sites nationwide.

With a 25-year heritage in Vietnam, AstraZeneca has supported the country’s healthcare development since 1994. Following the recent licensing, the company will provide over 500 high-quality jobs in biomedical sciences and medical affairs as well as sales and marketing, giving talented Vietnamese professionals major development opportunities and exposure to AstraZeneca’s global operations.

As part of its global vision, AstraZeneca aims to play a leading role in reducing the prevalence of Non-Communicable Diseases (NCDs) by building a patient-centric ecosystem to deliver meaningful improvements along the entire patient experience - from prevention and awareness to diagnosis, treatment, and post-treatment.

Earlier this year, the company announced a five-year investment of around $216 million in Vietnam in the 2020-2024 period. The investment will accelerate AstraZeneca’s existing efforts in helping to expand patients’ access to healthcare, through partnerships in training and improving the capacity of healthcare practitioners at the grassroots level to increase early diagnosis and provide the right treatment for patients.

The Healthy Lung program, a project in partnership with MSA and three local professional associations to enhance asthma and COPD management, is a case in point. Another example is the Young Health Program (YHP), to empower young people and their communities to pursue healthy lifestyles to prevent NCDs at an early stage of life.

User comment (0)

Send comment